22 JULY

High Recruitment: Twice as many patients as global CRO

Overview


Faced with a challenging recruitment process, needing to recruit a large number of elderly participants within a tight three-month seasonal recruitment window, a US-based Biotech Company appointed PharmaSols as the NZ CRO for this phase three respiratory clinical trial.

Having previously worked with PharmaSols over a number of trials, the US sponsor knew that the PharmaSols team could deliver on both tight start-up timelines and high recruitment targets. PharmaSols proven record of flexible, rapid, and creative solutions meant we were the ideal CRO partner.

Understanding New Zealand’s centralised ethics and regulatory bodies' processes and timelines, PharmaSols swiftly obtained the necessary Ethics and Regulatory approvals prior to the first site initiation visit (SIV). These short start-up timelines gave us a competitive advantage in recruiting significantly more participants than our global CRO partner across the same number of trial sites.


Challenges


There were several challenges while supporting this study:

  • Tight timelines
  • Needing to obtain ethics and regulatory approval quickly
  • Recruiting a large number of research participants in a short period
  • Engaging an elderly population to participate in a research trial
  • Using established site relationships for successful recruitment

Taking advantage of New Zealand’s diverse participant population, we engaged with trial sites with proven histories of high patient recruitment. We worked closely with these sites to develop successful strategies that recruited over 600 patients within our short three-month timeframe.


We assigned to the trial an experienced team and ensured there was a higher ratio of CRAs to support the trial sites. In keeping with our people-driven approach, we prioritised the sites' needs to maintain patient retention. This meant that part of our criteria for CRA selection was that they needed to be based near the sites, allowing them to respond rapidly to any problems and assist with high recruitment and peaks in monitoring activities.

Outcome

Our innovative approach to challenges like these enabled us to meet our client’s deadline efficiently. PharmaSols obtained the first SIV in less than 35 days and recruited almost twice as many patients as our global CRO partner over the 3 month recruitment period.

Case Studies

Expedited Timelines and Recruitment Success for COVID-19 Vaccine Trial

While the pandemic has slowed down most of the globe, it has increased the demand for rapid solutions within the pharmaceutical industry, with an urgent need to find a vaccine and COVID-19 related treatments and vaccines. Running clinical trials for potential solutions is a vital element in this process.

Read more
Exceeding Site Identification Targets Across Three Recent Clinical Trial Studies

Site identification is the first and most critical deliverable from a CRO. Without an appropriate site, there is no patient recruitment, and without patients, there is no study.

Read more
Rapid start-up: First SIV in less than 35 days

Having previously worked with PharmaSols over a number of trials, the US sponsor knew that the PharmaSols team could deliver on both tight start-up timelines and high recruitment targets. PharmaSols proven record of flexible, rapid, and creative solutions meant we were the ideal CRO partner.

Read more
Creative Solutions for US Biotech Clinical Trial

A US-based Biotech company was seeking a CRO who could successfully recruit a large number of elderly research participants in New Zealand. A challenge that was not only squeezed into a three-month seasonal recruitment window but was also met with issues so unique, there were no established protocols.

Read more
Rapid Start-up and Tight FPI Timeline for US Biotech Clinical Trial

After a sudden decision to expedite their study timelines, a US Biotech company approached PharmaSols in need of a CRO who could successfully achieve a quality rapid start-up within a tight timeline.

Read more
Quick Feasibility for Rare Genetic Trial

A US Biotech company reached out to PharmaSols, to investigate the feasibility of running a trial in New Zealand on participants' stored tissue samples, where consent had been given for further research to identify a rare genetic marker.

Read more